Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks...
11 insider purchases on record · latest filing 2023-10-06.
Insiders have also filed 45 sale transactions at CVKD.